Get started
Author

Andrée Rorive

Observed names: A Rorive, A. Rorive, Andree Rorive, Andrée RORIVE, RORIVE, Andrée, Rorive, Andrée
OpenAlex ID: A5087842420
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
2018 · Viviana Galimberti, Bernard F Cole, et al. · The Lancet Oncology · 575
Codon-specific translation reprogramming promotes resistance to targeted therapy
2018 · Francesca Rapino, Sylvain Delaunay, et al. · Nature · 271
18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers
2010 · Nadia Withofs, Benjamin Grayet, et al. · Nuclear Medicine Communications · 92
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes
2014 · Guy Jerusalem, Andree Rorive, et al. · Breast Cancer Targets and Therapy · 41
PDF
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
2025 · Alicia F. C. Okines, Giuseppe Curigliano, et al. · Nature Medicine · 25
PDF
Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).
2017 · Dirk Schadendorf, Paolo Antonio Ascierto, et al. · Journal of Clinical Oncology · 25
Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.
2015 · Lore Decoster, Isabelle Vande Broek, et al. · PubMed · 24
PDF
Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases
2012 · F. Libon, J. E. Arrese, et al. · Clinical and Experimental Dermatology · 22
Melanoma masquerading as nonmelanocytic lesions
2016 · Audrey Detrixhe, Florence Libon, et al. · Melanoma Research · 20
Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab
2008 · G. H. Jerusalem, V. Dieras, et al. · Journal of Clinical Oncology · 20
Recurrent In Situ Melanoma Successfully Treated with Ingenol Mebutate
2014 · Marion Mansuy, Nazli Nikkels-Tassoudji, et al. · Dermatology and Therapy · 19
PDF
Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab.
2009 · A Fasolo, L Gianni, et al. · Cancer Research · 19
The impact of COVID-19 on the new diagnoses of melanoma
2021 · Christophe Gedeah, Thomas Damsin, et al. · European Journal of Dermatology · 18
PDF
Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer
2015 · Guy Jerusalem, Andrée Rorive, et al. · Future Oncology · 17
Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL
2023 · Anne Rogiers, Laurence Willemot, et al. · Cancers · 16
PDF
Cemiplimab for locally advanced and metastatic basal cell carcinoma
2022 · Thomas Damsin, Eve Lebas, et al. · Expert Review of Anticancer Therapy · 16
Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy
2019 · Gabrielle Giet, Eve Lebas, et al. · Case Reports in Dermatology · 15
PDF
[Clinical case of the month. A case of acute rhabdomyolysis].
1999 · A Rorive, V Fraipont, et al. · PubMed · 15
Targeting ferroptosis resistance resensitizes metastatic HR + HER2 − breast cancer cells to palbociclib‐hormone therapy
2025 · Charles Pottier, Laetitia Montero‐Ruiz, et al. · 癌症：英文版 · 14
PDF
Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel
2021 · Eve Lebas, Nathalie Marchal, et al. · Expert Review of Anticancer Therapy · 13
Triple Negative Breast Cancer
2010 · P Freres, J Collignon, et al. · The Cancer Journal · 9
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey
2025 · Axel Hauschild, Claus Garbe, et al. · The Lancet Oncology · 6
Pre-study and in-study validation of a SPE-LC–MS–MS method for the determination of 5-S-cysteinyldopa, a melanoma biomarker, in human plasma
2011 · Gaëlle Martin, François Mansion, et al. · Talanta · 6
Diagnostic and therapeutic management of carcinoma of unknown primary: radio-imaging investigations
2006 · G. Jerusalem, A. Rorive, et al. · Annals of Oncology · 6
Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study.
2024 · Alicia Frances Clare Okines, Giuseppe Curigliano, et al. · Journal of Clinical Oncology · 5
PDF
Works count: 114
Citation count: 1,370
H-index: 16
I10-index: 20
Year
Topic
Type